This research study involves a combination of three drugs given together as a possible treatment for malignant rhabdoid tumor, atypical teratoid rhabdoid tumor, epithelioid sarcoma, chordoma or other tumors that are deficient in one of two possible proteins, either INI-1 (SMARCB1) or SMARCA4.
The names of the study drugs involved in this study are:
Tazemetostat (TAZVERIK)
Nivolumab (OPDIVO)
Ipilimumab (YERVOY)
Selected Eligibility
Ages 6 months to 21 years
Diagnosed with one of the following:
Atypical Teratoid Rhabdoid Tumor (ATRT)
Malignant Rhabdoid Tumor (MRT)
Rhabdoid Tumor of the Kidney (RTK)
Epithelioid Sarcoma
Chordoma (poorly differentiated or de-differentiated)
Other INI1- or SMARCA4-deficient tumors (with approval)
Must have completed initial treatment
Must meet performance and organ function criteria
Detailed inclusion and exclusion criteria are listed on clinicaltrials.gov
To inquire about this trial, please visit our patient referral page:
